title: Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants.
abstract: Combination therapy with protease inhibitors and nucleoside analogues dramatically suppresses plasma HIV-1 RNA and delays progression to AIDS, but the impact on HIV-associated malignancy remains to be established. We therefore examined incidence trends of Kaposi's sarcoma and non-Hodgkin's lymphoma in patients with advanced HIV infection in nine AIDS Clinical Trial Group studies of antiviral therapies for HIV and cytomegalovirus infections. Among a total of 6587 patients enrolled between November 1987 and February 1997, there were 280 cases of Kaposi's sarcoma and 68 cases of non-Hodgkin's lymphoma. Incidence rates per 100 person-years of both malignancies declined in concert with decreases in mortality, but the decreases in Kaposi's sarcoma were more profound and consistent than the decreases in non-Hodgkin's lymphoma. These data suggest that current therapies have ameliorated the incidence of Kaposi's sarcoma, but may not have had an equal effect on non-Hodgkin's lymphoma.
authors.affiliation: Viral Epidemiology Branch, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: C S
authors.initials: CS
authors.lastname: Rabkin
authors.forename: M A
authors.initials: MA
authors.lastname: Testa
authors.forename: J
authors.initials: J
authors.lastname: Huang
authors.forename: J H
authors.initials: JH
authors.lastname: Von Roenn
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D019380:Anti-HIV Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy; D017245:Foscarnet / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D019469:Indinavir / Q000627:therapeutic use; D016483:Lymphoma, AIDS-Related / Q000150:complications / Q000453:epidemiology*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000453:epidemiology*; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000150:complications / Q000453:epidemiology*
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D017245:Foscarnet; D019469:Indinavir; D015774:Ganciclovir